Quality Systems – Page 267

Pet Failure during cooling and moulding: CAPA with effectiveness checks for auditors

Understanding and Addressing Pet Failure during Cooling and Moulding in Pharmaceutical Manufacturing In pharmaceutical manufacturing, particularly in the production of dosage forms like rectal and vaginal preparations, pet failures during…

Ccit Failure during sterile filtration: FDA-ready investigation report and batch disposition

Ccit Failure in Sterile Filtration: A Comprehensive Investigation Guide In the world of pharmaceutical manufacturing, maintaining the integrity of processes such as sterile filtration is crucial, particularly in ophthalmic dosage…

Microbial Limits Failure after excipient change: packaging integrity and stability justification

Investigation of Microbial Limits Failures Following an Excipient Change In the pharmaceutical manufacturing space, excipient changes can precipitate unforeseen microbial limits failures, prompting concerns about product safety and compliance. This…

Viscosity Drift during bulk hold: packaging integrity and stability justification

Understanding and Addressing Viscosity Drift Issues during Bulk Hold in Pharmaceutical Manufacturing In the context of pharmaceutical manufacturing, viscosity drift during the bulk hold stage can be a critical concern,…

Content Uniformity Failure in suppository manufacturing: packaging integrity and stability justification

Investigating Content Uniformity Failures in Suppository Manufacturing: Ensuring Packaging Integrity and Stability Justification Content uniformity is a critical aspect of pharmaceutical manufacturing, especially when dealing with suppositories. A failure in…

Fill Weight Variability after temperature excursion: GMP investigation and batch disposition

Assessing Fill Weight Variability After Temperature Excursions: A Structured GMP Investigation Pharmaceutical manufacturing is inherently complex, with multiple factors influencing the final product’s quality. One common issue that can arise…

Osmolality Oos after packaging change: FDA-ready investigation report and batch disposition

Investigating Osmolality Out-of-Specification After Packaging Change In the pharmaceutical manufacturing sector, adherence to stringent quality standards is paramount. Recently, a situation arose where a batch of ophthalmic dosage forms exhibited…

Packaging Leakage Complaint in suppository manufacturing: GMP investigation and batch disposition

GMP Investigation of Packaging Leakage Complaints in Suppository Manufacturing Packaging leakage in suppository manufacturing can lead to significant quality concerns, product loss, and regulatory scrutiny. For pharmaceutical professionals involved in…

Suppository Deformation during inspection readiness: CAPA with effectiveness checks for auditors

Addressing Suppository Deformation: A Comprehensive Investigation Guide for Inspection Readiness In the world of pharmaceutical manufacturing, one persistent challenge is the deformation of suppositories observed during inspection. This issue not…

Osmolality Oos during sterile filtration: sampling, filtration, and EM controls

Investigation of Osmolality OOS During Sterile Filtration: A Practical Approach The pharmaceutical industry often encounters out-of-specification (OOS) results, particularly concerning osmolality during sterile filtration processes for ophthalmic dosage forms. Such…

Viscosity Drift during bulk hold: GMP investigation and batch disposition

Investigating Viscosity Drift during Bulk Hold in GMP Compliance In the realm of pharmaceutical manufacturing, maintaining the integrity of product characteristics during bulk holds is paramount. A drift in viscosity…

Cooling Tunnel Variability after excipient change: manufacturing vs lab root cause decision tree

Investigation into Cooling Tunnel Variability Following Excipient Change Variability in cooling tunnel performance can significantly impact pharmaceutical manufacturing processes, particularly after an excipient change. This can lead to Out of…